Drugs / CD19 CAR-γδ T cell
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07535138 | May 2026 → Jun 2028 expected | IgA glomerulonephritis, lupus nephritis, membranous glomerulonephritis | Air Force Military Medical University, China | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 CAR-γδ T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07535138 ↗ |
| Modality | Cell therapy | “cellular therapy” NCT07535138 ↗ |
| Route | Intravenous | “single intravenous infusion of CD19 CAR-γδ T cells” NCT07535138 ↗ |
| Target | CD19 | “CD19-Targeted Universal CAR-γδ T Cells” NCT07535138 ↗ |